TY - JOUR
T1 - Optimizing treatment outcomes in HIV-infected patients with substance abuse issues
AU - Celentano, David D.
AU - Lucas, Greg
N1 - Funding Information:
Supplement sponsorship. This article was published as part of a supplement entitled “Opportunities for Improving the Diagnosis of, Prevention of, and Access to Treatment for HIV Infection in the United States,” sponsored by the American Academy of HIV Medicine, amfAR, the Centers for Disease Control and Prevention, the Forum for Collaborative HIV Research, the HIV Medicine Association of the Infectious Diseases Society of America, and the National Institute of Allergy and Infectious Diseases. Potential conflicts of interest. D.D.C. and G.L.: no conflicts.
Funding Information:
The “Opportunities for Improving HIV Diagnosis, Prevention & Access to Care in the U.S.” conference was sponsored by the American Academy of HIV Medicine, amfAR, the Centers for Disease Control and Prevention, the Forum for Collaborative HIV Research, the HIV Medicine Association of the Infectious Diseases Society of America, and the National Institute of Allergy and Infectious Diseases. Funding for the conference was supplied through an unrestricted educational grant from Gilead Sciences, amfAR, GlaxoSmithKline, Pfizer, Abbott Virology, OraSure Technologies, Roche Diagnostics, and Trinity Biotech.
PY - 2007/12/15
Y1 - 2007/12/15
N2 - Drug abuse is associated with poorer virologic and clinical outcomes for patients with human immunodeficiency virus (HIV) infection. Limited evidence, primarily from in vitro and animal studies, shows that some abused drugs (e.g., opioids) may have direct effects on HIV pathology and the immune response to infection, but the clinical effects are not known. Clinical data indicate that the primary effect of drug abuse on HIV disease progression is mediated via factors that may limit access and/or adherence to highly active antiretroviral therapy (HAART). Drug abuse is associated with reduced adherence to HAART, which is strongly correlated with poorer virologic and clinical outcomes. However, the virologic and clinical effects of HAART are generally equivalent among drug abusers and non-drug abusers who adhere to therapy. These results underscore the importance of integrating medical and substance abuse interventions for HIV-positive drug abusers, to improve adherence to HAART and optimize outcomes of treatment for HIV infection.
AB - Drug abuse is associated with poorer virologic and clinical outcomes for patients with human immunodeficiency virus (HIV) infection. Limited evidence, primarily from in vitro and animal studies, shows that some abused drugs (e.g., opioids) may have direct effects on HIV pathology and the immune response to infection, but the clinical effects are not known. Clinical data indicate that the primary effect of drug abuse on HIV disease progression is mediated via factors that may limit access and/or adherence to highly active antiretroviral therapy (HAART). Drug abuse is associated with reduced adherence to HAART, which is strongly correlated with poorer virologic and clinical outcomes. However, the virologic and clinical effects of HAART are generally equivalent among drug abusers and non-drug abusers who adhere to therapy. These results underscore the importance of integrating medical and substance abuse interventions for HIV-positive drug abusers, to improve adherence to HAART and optimize outcomes of treatment for HIV infection.
UR - http://www.scopus.com/inward/record.url?scp=40949128781&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=40949128781&partnerID=8YFLogxK
U2 - 10.1086/522557
DO - 10.1086/522557
M3 - Review article
C2 - 18190306
AN - SCOPUS:40949128781
SN - 1058-4838
VL - 45
SP - S318-S323
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - SUPPL. 4
ER -